期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

半相合异基因造血干细胞移植后环磷酰胺预防移植物抗宿主病治疗复发难治性重型再生障碍性贫血十例

原文传递
导出
摘要 目前复发难治性重型再生障碍性贫血（SAA）患者主要通过造血干细胞移植治疗来改善疗效.2013年以来,我们受相关文献的启发,异基因造血干细胞移植后采用大剂量环磷酰胺诱导免疫耐受的方法,联合他克莫司、吗替麦考酚酯预防移植物抗宿主病（GVHD）,HLA半相合异基因造血干细胞移植（allo-SCT）治疗SAA 10例,现报告如下.
作者 楼金星 陈惠仁 刘晓东 郭智 张媛 杨凯 何学鹏 陈鹏 童春
机构地区 北京军区总医院血液病科
出处 《中华器官移植杂志》 CAS CSCD 2015年第12期748-749,共2页 Chinese Journal of Organ Transplantation
基金 基金项目：首都临床特色应用与成果推广研究（Z151100004015218）
关键词 异基因造血干细胞移植 重型再生障碍性贫血 移植物抗宿主病 HLA半相合 移植治疗 环磷酰胺 难治性 移植后
分类号 R457.7 [医药卫生—治疗学]
  • 相关文献

参考文献11

  • 1Luznik L,Fuchs EJ. High-dose, post-transplantationcyclophosphamide to promote graft-host tolerance afterallogeneic hematopoietic stem cell transplantation [ J ].Immunologic research, 2010,47(1-3) :65-77.
  • 2Luznik L, O" Donnell PV, Fuchs EJ. Post-transplantationcyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation[J]. Seminars inoncology, 2012, 39(6):683-693.
  • 3Luznik L, Jones RJ, Fuchs EJ. High-dose cyclophosphamidefor graft-versus-host disease prevention[J]. Current opinion inhematology, 2010,17(6) :493-499.
  • 4Luznik L,Bola os-Meade J,Zahurak M, et al. High-dosecyclophosphamide as single-agent, short-course prophylaxis ofgraft-versus-host disease [J]. Blood, 2010,115 (16) : 3224-3230.
  • 5Brodsky RA, Luznik L,Bola os-Meade J, et al. Reducedintensity HLA-haploidentical BMT with post transplantationcyclophosphamide in nonmalignant hematologic diseases [J].Bone marrow transplantation, 2008,42(8) :523-527.
  • 6Fuchs EJ. Human leukocyte antigen-haploidentical stem celltransplantation using T-cell-replete bone marrow grafts [J].Curr Opin Hematol? 2012,19(6):440-447.
  • 7Bolanos-Meade J,Fuchs EJ, Luznik L, et al. HLAhaploidentical bone marrow transplantation withposttransplant cyclophosphamide expands the donor pool forpatients with sickle cell disease. Blood 2012,120: 4285-4291.
  • 8Raj K, Pagliuca A? Bradstock K, et al. Peripheral bloodhematopoietic stem cells for transplantation of hematologicaldiseases from related, haploidentical donors after reduced-intensity conditioning. Biol Blood Marrow Transplant. 2014?20: 890-895.
  • 9Gupta N, Choudhary D,Sharma SK, et al. Haploidenticalhematopoietic SCT for acquired severe aplastic anemia usingpost-transplant high-dose CY. Bone Marrow Transplant.2015, 50(1):155-156.
  • 10Clay J? Kulasekararaj AG,Potter V, et al. Nonmyeloablativeperipheral blood haploidentical stem cell transplantation forrefractory severe aplastic anemia [ J ]. Biol Blood MarrowTransplant, 2014, 20(11):1711-1716.

二级参考文献14

  • 1Askar M,Sobecks R,Morishima Y. Predictions in the face of clinical reality:HistoCheck versus high-risk HLA allele mismatch combinations responsible for severe acute graftversus-host disease[J].{H}Biology of Blood and Marrow Transplantation,2011,(9):1409-1415.
  • 2Kawase T,Morishima Y,Matsuo K. High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism[J].{H}Blood,2007,(7):2235-2241.
  • 3Morishima Y,Yabe T,Matsuo K. Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor[J].{H}Biology of Blood and Marrow Transplantation,2007,(3):315-328.
  • 4Kanda Y,Chiba S,Hirai H. Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade(1991-2000)[J].{H}Blood,2003,(4):1541-1547.
  • 5Luznik L,O'Donnell PV,Symons HJ. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and highdose,posttransplantation cyclophosphamide[J].{H}Biology of Blood and Marrow Transplantation,2008,(6):641-650.
  • 6ODonnell PV,Luznik L,Jones RJ. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide[J].{H}Biology of Blood and Marrow Transplantation,2002,(7):377-386.
  • 7Ho VT,Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation[J].{H}Blood,2001,(12):3192-3204.
  • 8Luznik L,Engstrom LW,Iannone R. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation[J].{H}Biology of Blood and Marrow Transplantation,2002,(3):131-138.
  • 9Mayumi H,Himeno K,Tokuda N. Drug-induced tolerance to allografts in mice.Ⅶ.Optimal protocol and mechanism of cyclophosphamide-induced tolerance in an H-2 haplotype-identical strain combination[J].{H}TRANSPLANTATION PROCEEDINGS,1986,(2):363-369.
  • 10Luznik L,Bolanos-Meade J,Zahurak M. High-dose cyclophosphamide as single-agent,short-course prophylaxis of graft versus-host disease[J].Blood,2010,(16):3224-3230.

共引文献5

中华器官移植杂志
2015年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部